Stonebrook Private Inc. Invests $1.49 Million in Eli Lilly and Company (NYSE:LLY)

Stonebrook Private Inc. acquired a new stake in Eli Lilly and Company (NYSE:LLY) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 2,560 shares of the company’s stock, valued at approximately $1,493,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $26,000. Thompson Investment Management Inc. acquired a new stake in Eli Lilly and Company during the 3rd quarter worth approximately $27,000. Legacy Financial Group LLC acquired a new stake in Eli Lilly and Company during the 3rd quarter worth approximately $35,000. Optiver Holding B.V. acquired a new stake in Eli Lilly and Company during the 3rd quarter worth approximately $36,000. Finally, Family CFO Inc acquired a new stake in Eli Lilly and Company during the 3rd quarter worth approximately $40,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 1.2 %

Shares of NYSE:LLY traded up $8.64 during trading on Friday, hitting $733.51. 2,009,249 shares of the company’s stock were exchanged, compared to its average volume of 2,265,427. Eli Lilly and Company has a 1-year low of $380.77 and a 1-year high of $800.78. The firm has a 50-day moving average price of $761.79 and a two-hundred day moving average price of $666.67. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The firm has a market cap of $696.95 billion, a P/E ratio of 126.47, a PEG ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter in the previous year, the company earned $2.09 EPS. Eli Lilly and Company’s revenue was up 28.1% on a year-over-year basis. Equities analysts predict that Eli Lilly and Company will post 12.51 earnings per share for the current year.

Analysts Set New Price Targets

LLY has been the subject of several recent research reports. Barclays increased their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. BMO Capital Markets increased their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Morgan Stanley raised their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Truist Financial restated a “buy” rating and set a $850.00 price objective on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Finally, TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $728.05.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the business’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the sale, the insider now owns 99,488,598 shares of the company’s stock, valued at $64,177,109,911.86. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.